Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call reveals strong cost control and EBITDA growth, but a significant GAAP net loss due to impairment charges. The Q&A highlights pressures on data platform revenue and unclear management responses about strategic review and future guidance. Despite some positive product development and business updates, the overall sentiment is negative due to financial uncertainties and lack of clear guidance.

Key Financial Performance

Full Year 2025 Revenue $311.1 million, a 1% year-over-year growth. The growth was driven by a 7% increase in technology revenue to $208.3 million, offset by an 8% decline in professional services revenue due to prioritization of margin improvement and resource efficiency.

Fourth Quarter 2025 Revenue $74.7 million, compared to $79.6 million in the prior year period, reflecting a decline primarily due to lower professional services revenue from reductions in FTE service offerings and exit of unprofitable pilot ambulatory TAMS arrangements.

Adjusted Gross Margin for Full Year 2025 51.1%, driven by technology gross margin of 67.4% and professional services gross margin of 18.3%. This was an improvement from the prior year, reflecting benefits from restructuring actions, partially offset by migration-related cost headwinds.

Adjusted Operating Expenses for Full Year 2025 $117.7 million, representing 38% of revenue compared to $123.4 million or 40% of revenue in 2024. The decrease was due to restructuring actions, disciplined headcount management, and tighter control over discretionary spending.

Adjusted EBITDA for Full Year 2025 $41.4 million, representing a 59% year-over-year growth. This growth was attributed to strong cost control and operating leverage.

GAAP Net Loss for Full Year 2025 $178 million, compared to $69.5 million in 2024. The increase in loss was primarily due to impairment charges on goodwill and intangible assets of $110.2 million, driven by a decrease in consolidated market cap and revisions to forecasts.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Ignite Data and Analytics platform: Focus on deployment and development, with timing and status of migrations being a key area of discussion.

AI-enabled solutions: Investments in AI and leveraging data assets to drive competitive differentiation.

New client acquisition: 32 net new logos in 2025, exceeding the target of 30 but below the initial expectation of 40.

Client retention: Tech plus TAMs dollar-based retention closed the year at 93%.

Cost structure review: Strategic allocation of capital with increased discipline, focusing on expanding technology bookings and margins while driving cash flow generation.

Operational efficiency: Restructuring actions led to improved adjusted gross margin (51.1% for 2025) and reduced adjusted operating expenses (38% of revenue for 2025).

Migration-related challenges: Pressure from DOS to Ignite migration, with $12.5 million in ARR downsell and churn notified for 2026-2027.

Leadership changes: New CEO Ben Albert appointed, with a focus on clarity, discipline, and execution.

Simplification and focus: Efforts to reduce complexity in go-to-market motions, packaging, and implementation to improve client value realization.

Commercial strategy: Sharpening and simplifying the commercial story to better articulate value across cost efficiency, clinical quality, and consumer experience.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Leadership Transition: The recent CEO transition and ongoing searches for key leadership roles (COO and CMO) may create temporary instability and impact strategic execution.

Operational Complexity: Excessive complexity in go-to-market motions, packaging, and implementation has created friction for clients and slowed value delivery.

Cost Structure and Resource Allocation: The company is reviewing its cost structure to ensure strategic capital allocation, but this process may lead to disruptions or inefficiencies in the short term.

Revenue Decline: Year-over-year revenue decline in Q4 2025, primarily due to reductions in professional services revenue and exit from unprofitable arrangements.

Migration Challenges: Pressure from DOS to Ignite migrations has led to churn and downsell, with $12.5 million in ARR already notified for churn and $52 million potentially at risk in 2026-2027.

Market Demand Environment: Dynamic demand environment and lower-than-expected net new logos in 2025 indicate challenges in client acquisition and retention.

Impairment Charges: $110.2 million in impairment charges on goodwill and intangible assets due to market cap decrease and forecast revisions, impacting financial stability.

Short-Term Financial Pressure: Investments in migration-related personnel, contractors, and R&D (AI and India) may create near-term financial strain despite long-term benefits.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

First Quarter 2026 Revenue and Adjusted EBITDA Guidance: The company expects total revenue of $68 million to $70 million and adjusted EBITDA of $7 million to $8 million for Q1 2026.

Full Year 2026 Guidance: The company has not provided full-year guidance yet but plans to do so by the first quarter earnings call in May 2026.

Migration-Related Revenue Impact: The company anticipates a $1.5 million decline in Q1 2026 revenue due to DOS to Ignite migration pressure. Across 2026 and 2027, $12.5 million in DOS-related ARR downsell and churn has been notified, with $52 million in DOS-related ARR subject to negotiation.

Technology ARR Retention and Bookings: The company will focus on improving technology ARR retention and driving technology-led bookings through a sharper commercial approach.

Operational Efficiency and Investments: The company is investing in migration-related personnel, contractors, R&D in AI, and India, which may create near-term financial pressure but are expected to improve the cost structure in the second half of 2026 and beyond.

Post-2027 Migration Headwinds: The company expects to be through the data platform infrastructure migration headwind after 2027, with plans to retain a large part of the $35 million in data platform infrastructure ARR subject to negotiation.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Does the strategic review include the possibility of selling the company?

A:The CEO, Benjamin Albert, stated that the company is focused on positioning itself for long-term success and shareholder value. He did not directly confirm or deny the possibility of selling the company, emphasizing that they are in an assessment phase.

Q:Can you provide more details on the transition impact related to the first quarter and the $52 million in data platform revenue for the remainder of the year?

A:CFO Jason Alger explained that the $52 million in DOS-related revenue includes integrated applications and data platform infrastructure. The data platform infrastructure, particularly the hosting side, is under the most pressure, with $35 million of ARR being worked on for retention. This pressure is expected to continue into 2026 and 2027.

Q:Are clients choosing another platform or a competitor for the data platform infrastructure?

A:CEO Benjamin Albert mentioned that cross-industry technology solutions are available depending on client strategy. However, clients still rely on Health Catalyst for expertise, IP, and applications, which are part of their strategy to meet client needs.

Q:What did you learn in Q4 about bookings, deal size, sales cycle length, and app attach rates? How does this translate into expectations for 2026?

A:CEO Benjamin Albert noted that the market needs solutions to manage costs, drive clinical quality, and attract consumers. Clients face profitability pressures, changing payer mixes, and rising costs. The company sees opportunities in cost and labor management and clinical quality, which are reflected in their sales funnel.

Q:Where does Health Catalyst see its 'right to win' with its current portfolio?

A:CEO Benjamin Albert emphasized the company's strength in managing costs and driving clinical quality without compromising healthcare quality. He highlighted their 15 years of experience, extensive content, and intellectual property. The company is working on better storytelling and marketing to communicate its value proposition.

Q:What is the split between customers rolling off completely versus downselling?

A:CFO Jason Alger stated that enterprise relationships are rarely lost. Pressure is mainly on the data platform infrastructure side, leading to downselling. Clients generally retain application relationships.

Q:What are the specific Health Catalyst apps that fit into cost and clinical quality categories, and how do they address these needs?

A:CEO Benjamin Albert mentioned apps like clinical cost intelligence, power labor, and consumer intelligence. These apps help manage costs, improve clinical quality, and support ambulatory and consumer strategies. The company focuses on solving client challenges while maintaining or improving clinical quality.

Q:How durable are margins if revenue remains under pressure, and what are the levers for 2026?

A:CFO Jason Alger explained that gross margins face pressure due to duplicate hosting costs and migration personnel costs. These costs are expected to impact 2026 and partially 2027 but will be removed post-migration. The company is still evaluating growth expectations for 2026 and 2027.

Q:What is the breakdown of the $65 million DOS-related ARR at risk, and what is the success rate for retaining it?

A:CFO Jason Alger stated that $12.5 million of ARR is expected to impact 2026, mostly in the latter half. Of the $52 million at risk, $35 million is related to data infrastructure. The company expects some downselling but aims to retain application relationships. More details will be provided in the next earnings call.

Q:Which acquisitions have shown decent growth and align with the company's priorities?

A:CEO Benjamin Albert stated that most applications align with the company's priorities of cost management, clinical quality, and consumer engagement. The company is assessing which applications create the most value and will provide more clarity in the next earnings call.

Q:Review of Unclear Management Responses

A:The management avoided directly answering whether the strategic review includes selling the company. Additionally, they did not provide specific growth expectations for 2026 or 2027, stating that guidance will be provided in the next earnings call.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

LMNR Transcript

Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript

Unknown3-12

Limoneira Company (LMNR) Q1 2026 Earnings Call Transcript

Unknown3-12

The earnings call reveals several negative financial metrics: increased losses, reduced revenues, and higher debt. The Q&A section indicates pricing pressures and lack of immediate monetization strategies for water rights. Although management is optimistic about future avocado production and cost savings, current financial performance and market conditions present challenges. The lack of immediate positive catalysts, along with operational losses and uncertainties, suggest a likely negative stock price movement.

Limoneira Company (LMNR) Q4 2025 Earnings Call Transcript

Unknown12-23

The earnings call reveals significant financial challenges, with increased losses and declining revenues across key areas. Although there are positive strategic initiatives like the Sunkist partnership and real estate development, the Q&A section highlights uncertainties, particularly in cost savings timelines and financial impacts. The strategic transformation costs and power outages further exacerbate financial woes. The lack of specific guidance and the negative financial performance outweigh the potential long-term benefits of strategic initiatives, leading to a negative sentiment.

Limoneira Company (LMNR) Q3 2025 Earnings Call Transcript

Unknown9-9

The earnings call revealed multiple negative factors: increased debt levels, a net loss in Q3 FY2025, and a decline in adjusted EBITDA. Despite strategic plans like the merger with Sunkist and avocado production expansion, the financial performance was weak, with significant revenue and income declines. The Q&A session highlighted uncertainties in avocado volumes and management's unclear responses. These negative elements outweigh potential positives, leading to a 'Negative' sentiment rating for the stock price over the next two weeks.

LMNR Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.